Cancer immunotherapy drugs: immune checkpoint inhibitors
Ipilimumab——The first drug to receive approval by the Food and Drug Administration (FDA) for the treatment of advanced melanoma, blocks the activity of a checkpoint protein known as CTLA4, which is expressed on the surface of activated immune cells called cytotoxic T lymphocytes.
Nivolumab——Nivolumab is approved by FDA to treat some patients with advanced melanoma or advanced lung cancer targeting a checkpoint protein on activated T cells known as PD-1.
Pembrolizumab——pembrolizumab is approved by FDA to treat some patients with advanced melanoma targeting a checkpoint protein on activated T cells known as PD-1.
Cancer immunotherapy drugs: targeted monoclonal antibodies
Rituximab——Targeting a protein on the surface of B lymphocytes called CD20,approved to be used alone or with other drugs to treat: B-cell non-Hodgkin lymphoma (certain types) and Chronic lymphocytic leukemia (CLL).
Cetuximab——In combination with radiation therapy for the initial treatment of locally or regionally advanced SCCHN; as a single agent for patients with SCCHN for whom prior platinum-based therapy has failed; and palliative treatment of pretreated metastatic
EGFR-positive colorectal cancer.
Trastuzumab——ERBB2-positive breast cancer, as a single agent or in combination with chemotherapy for adjuvant or palliative treatment; ERBB2-positive gastric or gastro-oesophageal junction carcinoma as first-line treatment in combination with cisplatin and capecitabine or 5‑fluorouracil.
Cancer immunotherapy drugs: cancer vaccines
Sipuleucel-T—— In 2010, the FDA approved the first cancer treatment vaccine, sipuleucel-T (Provenge®), for use in some men with metastatic prostate cancer.
Bacillus Calmette-Guérin (BCG)——the first biological therapy to be approved by the FDA. Approximately 70 percent of patients with early-stage bladder cancer experience a remission after BCG therapy.
Cancer immunotherapy drugs: cytokines
Aldesleukin——IL-2 that is made in a laboratory, has been approved for the treatment of metastatic kidney cancer and metastatic melanoma.
Numerrous cancer immunotherapy drugs are under reseach and clinical trails now. And more and more drus will be approved used for cancer treatments.
Scott A M et al. Antibody therapy of cancer[J]. Nature Reviews Cancer, 2012, 12(4): 278-287.
Disis ML et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. Journal of Clinical Oncology 2009;27(28):4685-4692.